Fibrocell Science, Inc.
(NASDAQ : FCSC)

( )
FCSC PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
LLYEli Lilly & Co. 1.08%365.631.1%$1192.52m
JNJJohnson & Johnson 0.12%177.220.7%$1097.25m
MRKMerck & Co., Inc. 0.60%107.460.7%$994.87m
PFEPfizer Inc. 0.72%49.200.9%$981.12m
ABBVAbbVie, Inc. 0.14%159.611.9%$906.78m
BMYBristol-Myers Squibb Co. 0.16%79.271.1%$751.13m
AZNAstraZeneca Plc 0.08%66.171.0%$360.17m
IDXXIDEXX Laboratories, Inc. -1.24%411.363.9%$222.64m
GSKGSK Plc 0.89%33.990.3%$202.02m
HZNPHorizon Therapeutics Plc 0.97%78.285.4%$201.37m
NVSNovartis AG 0.57%87.790.2%$190.04m
CTLTCatalent, Inc. -1.83%41.411.9%$163.88m
ALNYAlnylam Pharmaceuticals, Inc. 2.03%212.728.0%$159.13m
NVONovo Nordisk A/S 0.86%118.840.1%$155.62m
SGENSeagen Inc. -0.42%123.445.7%$122.67m

Company Profile

Fibrocell Science, Inc., is an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications. The fibroblast cell plays a key role in the production of collagen and growth factors which support the skin and other soft tissues; therefore, these cells could play a key role in treating many medical conditions. They have a robust pipeline and clinical programs based on the autologous fibroblast cell. They believe their aesthetic indication is a beachhead for higher value indications. They have a strong base of knowledge and expertise in cell based product development, manufacturing and seeking regulatory approvals. Their focus is to enter clinical programs to treat medical conditions that have an unmet need, helping patients and creating more value per cell.